Alterations in Syncytiotrophoblast Cytokine Expression Following Treatment with Lipopolysaccharide
Ma Y, Mor G, Abrahams VM, Buhimschi IA, Buhimschi CS, Guller S. Alterations in Syncytiotrophoblast Cytokine Expression Following Treatment with Lipopolysaccharide. American Journal Of Reproductive Immunology 2005, 55: 12-18. PMID: 16364007, DOI: 10.1111/j.1600-0897.2005.00347.x.Peer-Reviewed Original ResearchConceptsCytokine expressionLPS treatmentInflammatory compoundsAnti-inflammatory cytokinesIL-8 levelsInterleukin-8 levelsAnti-inflammatory compoundsEnzyme-linked immunosorbent assayCell typesCytokine levelsGlucocorticoid treatmentMaternal bloodDEX treatmentPlacental syncytiumSyncytiotrophoblastImmunosorbent assayLPSPrimary culturesTreatmentCytokinesFourfold increaseExpressionSyncytiaGestationLevelsThrombin-dependent regulation of matrix metalloproteinase (MMP)-9 levels in human fetal membranes*
Stephenson CD, Lockwood CJ, Ma Y, Guller S. Thrombin-dependent regulation of matrix metalloproteinase (MMP)-9 levels in human fetal membranes*. The Journal Of Maternal-Fetal & Neonatal Medicine 2005, 18: 17-22. PMID: 16105787, DOI: 10.1080/14767050500123632.Peer-Reviewed Original ResearchConceptsMMP-9 levelsMMP-9MMP-1Matrix metalloproteinaseAmniochorionic membranesThrombin receptor agonist peptidePreterm premature ruptureAnti-inflammatory steroidsMajor risk factorMMP-9 expressionThrombin treatmentThrombin receptor agonistPresence of lipopolysaccharideHuman fetal membranesPremature ruptureReceptor agonistRisk factorsSuch hemorrhageDEX treatmentMMP levelsTIMP-1Thrombin receptorTissue inhibitorAgonist peptideFetal membranes